Bicara Therapeutics Inc. Common Stock
BCAX | NASDAQ
$22.01
-$0.63 (-2.78%)
At close: Sep 21, 2026, 4:00 PM ET
$22.01
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -201.99M | -174.06M | -155.6M | -141.12M | -121.07M | -108.8M | -82.39M | -69.44M | -58.34M | -46.93M | -39.89M | -26.2M | -16.67M | -8.34M |
Interest Income | 16.83M | 16.94M | 17.87M | 19.95M | 18.71M | 16.73M | 14.58M | 10.02M | 6.88M | 4.18M | 1.31M | 13K | n/a | n/a |
Pretax Income | -185.16M | -157.12M | -137.73M | -121.17M | -102.36M | -92.08M | -67.81M | -59.47M | -64.84M | -56.14M | -51.98M | -39.55M | -16.7M | -8.35M |
Net Income | -185.36M | -157.32M | -137.95M | -121.52M | -102.67M | -92.33M | -68M | -59.48M | -64.84M | -56.14M | -51.99M | -39.55M | -16.7M | -8.35M |
Selling & General & Admin | 42.75M | 35.8M | 30.51M | 29.13M | 26.19M | 22.88M | 18.77M | 15.14M | 12.97M | 10.84M | 9.28M | 6.15M | 3.56M | 1.78M |
Research & Development | 132.08M | 111.11M | 97.94M | 84.83M | 94.88M | 85.92M | 63.62M | 54.3M | 45.37M | 36.09M | 30.61M | 20.05M | 13.11M | 6.56M |
Other Expenses | 27.16M | 27.16M | 27.16M | 27.16M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 201.99M | 174.06M | 155.6M | 141.12M | 121.07M | 108.8M | 82.39M | 69.44M | 58.34M | 46.93M | 39.89M | 26.2M | 16.67M | 8.34M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 201.99M | 174.06M | 155.6M | 141.12M | 121.07M | 108.8M | 82.39M | 69.44M | 58.34M | 46.93M | 39.89M | 26.2M | 16.67M | 8.34M |
Income Tax Expense | 102K | 93K | 217K | 350K | 310K | 258K | 187K | 6K | 6K | 6K | 5K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 67.93M | 60.72M | 55.14M | 54.56M | 54.54M | 54.46M | 54.44M | 54.41M | 54.18M | 54.18M | 53.09M | 54.41M | 54.6M | 54.6M |
Shares Outstanding (Diluted) | 67.93M | 60.72M | 55.14M | 54.56M | 54.54M | 54.46M | 54.44M | 54.41M | 54.18M | 54.18M | 53.09M | 54.41M | 54.62M | 54.62M |
EPS (Basic) | -3.10 | -2.78 | -2.53 | -2.23 | -1.88 | -1.65 | -1.24 | -1.09 | -1.19 | -1.07 | -0.95 | -0.72 | -0.30 | -0.15 |
EPS (Diluted) | -3.10 | -2.78 | -2.53 | -2.23 | -1.88 | -1.65 | -1.24 | -1.09 | -1.19 | -1.07 | -0.95 | -0.72 | -0.30 | -0.15 |
EBITDA | -184.38M | -156.99M | -137.63M | -121.06M | -102.29M | -92.01M | -67.75M | -72.76M | -78.14M | -69.45M | -65.3M | -39.54M | -16.7M | -8.35M |
EBIT | -185.16M | -157.12M | -137.73M | -121.17M | -102.36M | -92.08M | -67.81M | -72.82M | -78.18M | -69.48M | -65.32M | -39.55M | -16.7M | -8.35M |
Depreciation & Amortization | 774K | 130K | 105K | 109K | 68K | 62K | 56K | 55K | 42K | 30.5K | 19K | 5K | 3K | 1.5K |
Add to Watchlist
Select watchlists to add or remove BCAX